Enhanced Access to Affordable Medicines Act of 2022
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 9, 2022
Referred to the Subcommittee on Health.
Mar 8, 2022
Introduced in House
Mar 8, 2022
Referred to the House Committee on Energy and Commerce.
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Plain-English summary
Enhanced Access to Affordable Medicines Act of 2022
This bill specifies that the Food and Drug Administration may approve generic drugs with different labels than the brand-name versions if, among other requirements, the brand-name drug is subject to an active patent or exclusivity period and a revised label for the brand-name drug is approved within 90 days (rather than 60 days) of the expiration of the patent or exclusivity period.
What's happening now
Referred to the Subcommittee on Health.
Related & companion bills
1
Bill text
1 version
- Introduced in House Formatted Text PDF Formatted XML
Committees of jurisdiction
2
Cosponsors
1
Cite this page
U.S. Congress. (2026). H.R. 6973: Enhanced Access to Affordable Medicines Act of 2022. 117th Congress. Open America. https://openamerica.io/bill/117-HR-6973/
"H.R. 6973: Enhanced Access to Affordable Medicines Act of 2022." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-6973/.
H.R. 6973, 117th Cong. (2026), https://openamerica.io/bill/117-HR-6973/.
[H.R. 6973: Enhanced Access to Affordable Medicines Act of 2022](https://openamerica.io/bill/117-HR-6973/)